Ipsen gives back Parkin­son’s drug af­ter fail­ing PhI­Ib study; Par­a­digm Ther­a­peu­tics gets glob­al rights to skin treat­ment

IR­LAB Ther­a­peu­tics has full rights to mes­dopetam again af­ter the drug flunked a Phase IIb study in­volv­ing Parkin­son’s pa­tients.

The com­pa­nies …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA